1. Home
  2. CVKD

CVKD

Cadrenal Therapeutics Inc.

Logo Cadrenal Therapeutics Inc.

Health Care

Medicinal Chemicals and Botanical Products

Nasdaq

as 04-18-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.

Founded: 2022 Country:
United States
United States
Employees: N/A City: PONTE VEDRA
Market Cap: 6.5M IPO Year: 2023
Target Price: $3.50 AVG Volume (30 days): 457.8K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.62 EPS Growth: N/A
52 Week Low/High: $0.36 - $3.14 Next Earning Date: 05-08-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: